Key Takeaways

• Ketamine is a DEA Schedule III controlled substance. Prescribing, administering, and storing ketamine require DEA registration for both the prescribing physician and (for stored inventory) the practice facility.
• Ryan Haight Act telemedicine flexibilities for controlled-substance prescribing are extended through December 31, 2026 under the DEA’s Fourth Temporary Extension. Permanent DEA rules are anticipated but not yet final. Buyers structuring around telemedicine-forward ketamine practice should plan for potential rule change.
• The California CPOM analysis applies fully. Ketamine practice is the practice of medicine, and the clinical entity has to be a physician-owned professional corporation under Cal. Corp. Code § 13401.5.
• Three delivery models — in-clinic IV/IM infusion, telehealth-only at-home dosing, and FDA-approved Spravato (esketamine) — carry meaningfully different compliance, insurance, and payor profiles. Buyer diligence has to identify which the target actually operates.
• California-specific: B&P § 2290.5 permits Schedule III prescribing via real-time audio-video telehealth after establishing the provider-patient relationship. AB 890’s 104 NP full-practice authority extends to Schedule III prescribing including ketamine, subject to the NP’s DEA registration.

Buying a Ketamine Clinic in California: A Non-Licensee Buyer’s Guide

Ketamine practice sits in a category that combines almost every California healthcare compliance layer at once. Ketamine is a Schedule III controlled substance, which brings the DEA into every aspect of the practice. It is prescribed almost entirely off-label for mental-health indications (treatment-resistant depression, PTSD, chronic pain), which brings the Medical Board’s off-label prescribing standards into the analysis. Most delivery is by IV infusion or intramuscular injection, which brings the IV administration, standardized procedures, and sterile compounding framework in. The Ryan Haight Online Pharmacy Consumer Protection Act governs telemedicine prescribing of controlled substances, and the DEA’s Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities allows telemedicine prescribing without a prior in-person visit — but only through December 31, 2026. And, separately from all of the above, Spravato (esketamine) is an FDA-approved product with its own REMS-restricted delivery framework.

A non-licensee buyer evaluating a California ketamine practice is looking at a target where every one of those layers has to be diligenced separately. This post walks through the ketamine-specific issues. It sits under the buyer pillar for the CPOM Acquisition & Remediation cluster and is the companion to the general treatment-business acquisition guide.

The Three Ketamine Delivery Models

The regulatory analysis depends heavily on which delivery model the target operates. Most buyer diligence starts here.

Model 1: In-clinic IV or IM infusion. The physician (or NP or PA within scope) evaluates the patient in person, prescribes ketamine, and the practice administers by IV infusion or intramuscular injection under clinical supervision. Sessions typically run 40 to 90 minutes with monitored recovery. This is the model most established ketamine practices use, and the model with the strongest regulatory footing across the current framework. Diligence emphasis: DEA registration (both physician and facility), sterile compounding sourcing (if the target compounds in-house or works with a 503A/503B pharmacy), standardized procedures for RN or CRNA administration under 16 CCR § 1474, and the clinical protocols for anesthesia-adjacent risk management.

Model 2: Telehealth-only at-home dosing. The physician evaluates the patient by telemedicine, prescribes low-dose oral or sublingual ketamine (compounded troches or rapid-dissolve tablets, since neither FDA-approved oral formulation exists), and the compounded product ships to the patient’s home. Sessions are self-administered with remote check-ins. This model expanded during COVID-era Ryan Haight flexibilities and has been the growth segment. Diligence emphasis: whether the practice has been operating within the Fourth Temporary Extension’s requirements; compounding pharmacy relationships (this model depends heavily on 503A patient-specific compounding); patient screening protocols and adverse-event monitoring; and — critically — how the practice plans to transition when Ryan Haight flexibilities expire or become permanent under different terms.

Model 3: FDA-approved Spravato (esketamine). The practice is enrolled in the Spravato REMS program and delivers esketamine intranasally under REMS-required in-office administration and monitoring. Spravato has commercial payor coverage in many markets and is the only ketamine-adjacent product with FDA approval for treatment-resistant depression. Diligence emphasis: REMS enrollment status, payor participation, prior-authorization workflow, and the physician-of-record’s Spravato certification. Most Spravato-focused practices have parallel racemic ketamine offerings; diligence has to identify both.

The three models are not mutually exclusive; larger practices often combine them. Diligence should identify which the target operates, which generate the most revenue, and which carry the most compliance exposure.

The Ryan Haight and Fourth Temporary Extension Overlay

For telehealth-forward ketamine practices, the Ryan Haight Act framework is the load-bearing regulatory feature and the fastest-aging item for the buyer.

The baseline rule. Ryan Haight (21 U.S.C. § 829(e)) generally requires a prescribing practitioner to conduct at least one in-person medical evaluation of the patient before prescribing controlled substances via telemedicine, subject to specific exceptions.

The COVID-era flexibility. Beginning March 2020, the DEA and HHS suspended the in-person examination requirement, allowing prescribing of Schedule II–V controlled substances after an audio-video telemedicine visit alone. This flexibility has been extended four times.

The current extension. The Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications — published in the Federal Register on December 31, 2025 — extends telemedicine flexibilities through December 31, 2026. Under this extension, a DEA-registered practitioner may prescribe Schedule II–V controlled substances (including ketamine) via audio-video telemedicine without a prior in-person evaluation, provided all other federal and state requirements are met.

The Two January 17, 2025 Final Rules. Separate from the temporary extension, the DEA and HHS finalized two narrower permanent rules (buprenorphine expansion and VA continuity) that took effect December 31, 2025. Together with the Fourth Temporary Extension, three distinct sets of telemedicine authorities now apply — a complexity that buyer’s counsel needs to translate for the specific practice’s prescribing patterns.

What’s coming. Permanent DEA telemedicine rules are anticipated but not final. The proposed Special Registration for Telemedicine framework, if adopted, would replace the temporary extension with a formal registration and reporting regime. Timing for the permanent rules has been repeatedly extended, and buyers should not assume the current flexibilities will continue past December 31, 2026 without further extension or replacement.

California overlay. B&P § 2290.5 permits Schedule III prescribing via real-time audio-video telehealth after establishing the provider-patient relationship. California’s telehealth framework operates alongside — not instead of — the federal Ryan Haight framework, so both apply.

Practical rules for the buyer.

• A telehealth-only ketamine target has business-continuity exposure tied to the December 31, 2026 flexibility expiration. Diligence should include a contingency plan for what the target’s operations look like if permanent DEA rules require in-person evaluation for controlled-substance prescribing.
• An in-clinic infusion target with in-person evaluation as the standard is not exposed to the Ryan Haight flexibility question in the same way, because in-person evaluation already meets the baseline rule.
• A hybrid target with both models needs both diligence tracks.

DEA Registration: Physician and Facility

Ketamine is Schedule III. Every physical location where ketamine is stored requires its own DEA registration tied to that specific address. The prescribing physician’s personal DEA registration authorizes the physician’s prescribing but does not cover facility storage.

The distinction is common ground where non-compliant ketamine practices — and other Schedule III practices, including TRT/HRT, get audited. A physician’s DEA registration is a prescribing credential; a facility DEA registration is a storage credential; they are separate.

Buyer diligence. Confirm:

• The prescribing physician’s DEA registration is active, current, and includes Schedule III authorization.
• Every physical location where ketamine is stored has its own DEA registration tied to that address.
• Inventory records for the last twelve months reconcile — ketamine in, ketamine administered, ketamine wasted, ketamine disposed.
• Disposal records comply with the Secure and Responsible Drug Disposal Act framework.
• CURES reporting (California’s PDMP) reflects the practice’s controlled-substance activity. (Note: unlike testosterone, ketamine is not subject to any CURES-reporting carve-out; ketamine prescriptions remain reportable to CURES.)

What a red-flag answer looks like. “The doctor keeps ketamine at the office under his personal DEA number.” “The registration was for the old location; we moved a year ago but haven’t updated.” “Inventory records? We track what we use; we don’t formally reconcile.”

The Compounding Layer

Many ketamine practices depend on compounded product. Two categories to diligence:

Injectable ketamine for in-clinic use. Commercial injectable ketamine (Ketalar and generic ketamine hydrochloride) is available and used in most established clinical practices. Some practices compound custom formulations from bulk ketamine substance — a much narrower and higher-scrutiny category. If the target uses compounded injectable ketamine, diligence should confirm the compounding pharmacy is properly registered (503A or 503B), USP 797-compliant, and the compounded formulation is clinically justified rather than economically motivated.

Oral / sublingual troches and rapid-dissolve tablets for at-home dosing. No FDA-approved oral ketamine product exists for the depression indications ketamine practices treat. Practices offering at-home telehealth dosing depend entirely on 503A compounding — patient-specific compounding by state-licensed pharmacies. This is legal when done properly and problematic when done wrong. Diligence should confirm the compounding pharmacy is state-licensed, USP 797-compliant, and that each patient prescription is genuinely patient-specific rather than a masked bulk-compounding operation.

What the FDA has flagged. The FDA’s 2023 patient safety notice specifically addressed compounded ketamine for at-home use, cautioning about the lack of REMS-style safety controls in the compounded context. Buyer’s counsel should assume that FDA and DEA attention to at-home compounded ketamine will remain elevated.

CPOM and the Ketamine-Specific Structural Analysis

The general CPOM framework applies. Ketamine practice is the practice of medicine. The clinical entity has to be a physician-owned professional corporation under Cal. Corp. Code § 13401.5. Non-licensee ownership of the clinical entity is not lawful. A non-licensee buyer acquires the target through the friendly-PC + MSO structure — the buyer’s MSO acquires non-clinical assets and provides services under an MSA to the physician-partner’s newly formed PC.

Three ketamine-specific structural notes:

Physician-partner considerations. Ketamine-experienced physicians come from psychiatry, anesthesiology, emergency medicine, and pain management. The physician-partner needs the appropriate DEA registration (Schedule III), professional liability coverage that includes ketamine administration (some general policies exclude), and the clinical background to defensibly evaluate patients for off-label ketamine treatment. Psychiatric evaluation training or partnership with a licensed psychotherapist for adjunctive care are common features of the higher-quality clinical model.

AB 890 104 NPs. California’s full-practice-authority NP category (the “104 NP”) can prescribe Schedule III controlled substances including ketamine, provided the NP holds an active individual DEA registration and has completed the 4,600-hour transition-to-practice period. Ketamine practices that scaled through NP-led clinical delivery may have 104 NPs as prescribers; diligence should confirm each NP’s DEA registration status and practice-authority classification.

Clinical safety infrastructure. Ketamine administration is anesthesia-adjacent — the practice needs monitored recovery, adverse-event protocols, staff CPR/BLS certification, emergency medications on-site (including for hypertensive response and respiratory depression), and appropriate clinical monitoring during sessions. Buyer’s counsel should confirm the target’s clinical safety infrastructure and the professional liability coverage’s alignment with the actual clinical model.

Marketing and Off-Label Prescribing Considerations

Ketamine is FDA-approved as an anesthetic. Every mental-health use — treatment-resistant depression, PTSD, chronic pain, suicidal ideation, addiction adjunct, is off-label. Off-label prescribing is lawful when clinically appropriate; marketing overstating the evidence for off-label indications is a separate exposure category.

Common ketamine marketing exposure patterns:

• Efficacy claims for treatment-resistant depression, PTSD, or suicidality that outrun the published evidence.
• Testimonials that overstate typical results.
• “Guaranteed” or “life-changing” language.
• Failure to distinguish racemic ketamine (off-label) from FDA-approved Spravato.
• Missing or inadequate disclosure of adverse-event risks (dissociation, hypertensive response, cardiovascular events, bladder toxicity with chronic use).

Buyer diligence should audit the target’s marketing history and identify the marketing rebuild scope for post-closing operations.

When to Bring Counsel Into a Ketamine Acquisition

Before the LOI is signed. Ketamine is a category where seller framings often outrun regulatory reality — “we have telehealth prescribing under DEA flexibility” doesn’t distinguish targets that have been operating within the Fourth Temporary Extension’s terms from targets that have been prescribing controlled substances outside them, and the difference matters enormously to the buyer.

Bay Legal, PC represents non-licensee buyers of California ketamine practices through pre-LOI structural counsel, DEA and CPOM diligence, and deal documentation. Call (650) 668-8000 or schedule a consultation at baylegal.com/contact.

Frequently Asked Questions

Can a non-doctor buy a ketamine clinic in California?

Yes, through the friendly-PC + MSO structure. A licensed physician acquires the clinical assets (patient records, clinical protocols, DEA-registered practice location if the buyer will continue operations at the same address) into a newly formed professional corporation. The buyer’s management entity acquires the non-clinical assets and provides services to the PC under a Management Services Agreement. Direct purchase of the seller’s LLC or continued operation through the LLC is not compliant.

Do the DEA telemedicine flexibilities still allow at-home ketamine treatment through 2026?

Yes, through December 31, 2026, under the DEA’s Fourth Temporary Extension published in the Federal Register on December 31, 2025. A DEA-registered practitioner may prescribe Schedule II–V controlled substances (including ketamine) via audio-video telemedicine without a prior in-person evaluation, provided all other federal and state requirements are met. Permanent DEA rules are anticipated but not final; buyers structuring around telemedicine-forward ketamine practice should plan for potential rule change after December 31, 2026.

Does the practice need its own DEA registration, or is the physician’s registration enough?

Both. The prescribing physician’s personal DEA registration authorizes the physician’s prescribing activity but does not cover facility storage of controlled substances. Every physical location where ketamine is stored requires its own DEA registration tied to that specific address. This is a common diligence finding — practices that store ketamine under only the physician’s personal registration are operating outside federal law and are exposed to DEA civil monetary penalties.

What is the difference between Spravato and racemic ketamine practices?

Spravato (esketamine, the S-enantiomer of ketamine) is FDA-approved for treatment-resistant depression, delivered intranasally under a REMS program that requires in-office administration and monitoring. It has commercial payor coverage in many markets and requires REMS enrollment. Racemic ketamine (the standard ketamine product used for anesthesia) is used off-label for depression, PTSD, and chronic pain by IV infusion, IM injection, or (for at-home telehealth) compounded oral formulations. Most established ketamine practices operate both models. Diligence has to identify each.

Can nurse practitioners prescribe ketamine in California?

Yes, subject to specific requirements. California’s AB 890 104 NP category (full-practice authority NPs who have completed the 4,600-hour transition-to-practice period) may prescribe Schedule III controlled substances including ketamine, provided the NP holds an active individual DEA registration. Traditional NPs operating under standardized procedures with a collaborating physician can also participate in ketamine prescribing within the standardized-procedures framework. Diligence should confirm each prescribing NP’s practice-authority category and DEA registration.

Talk to a California Ketamine Acquisition Attorney

Bay Legal, PC represents non-licensee buyers of California ketamine practices. If you are evaluating a ketamine target and want to structure the deal for CPOM, DEA, and Ryan Haight compliance from the beginning, call (650) 668-8000 or schedule a consultation at baylegal.com/contact.